BIOCORP

Strong Increase in Half-year Results as of June 30th, 2019 - Seite 3

- At the end of the period, BIOCORP has available cash of €333k (€1,341k on 31 December 2018) and shareholders' equity of €311k (€1,820k on 31 December 2018). On July 12, 2019, the receipt of €4,800,000 in trade receivables solidified the available cash position.

In €

June 30, 2019

June 30, 2018

Sales

5 247 993

1 960 655

Other operating income

65 941

- 186 198

Total operating income

5 313 934

1 774 457

Net operating income

1 199 173

-2 804 195

Net financial income

-59 705

- 95 017

Exceptional item

6 589

3 262

Research Tax Credit and Innovation Tax Credit

92 681

186 508

Net profit

1 238 737

-2 709 443

BIOCORP has made its half-yearly financial report for the financial year ended June 30, 2019 available to the public and filed it with the AMF. The document is available on the website www.biocorp.fr, heading "investors".

Objectives and outlook for the second half of 2019:

During the second half of 2019, BIOCORP intends to pursue its development in its various strategic areas:

• Connected devices: BIOCORP is preparing the commercial launch of Mallya^TM with its distribution partners and is already working on the new generations of this proprietary technology, either on its own or in partnership. Finally, during the second half of 2019, the Company intends to present a new injection device with very original characteristics based on BIOCORP's unique expertise in the field of connected devices.
• Industrialization of products, subject of signed contracts: continuation of partnerships regarding product development and industrialization. The connected devices will give rise to a new phase of industrialization, which will initially take place at the historic site (Issoire), while considering capacities expansion in the short term.
• Growth of the traditional activity: structuring the offer with a positioning for small to medium series on a set of plastic packaging products (cannulas, vials, caps, pipettes...).
• Specific developments: BIOCORP is solicited for its development and industrialization expertise, whether for the adaptation of its proprietary products for a particular use or for a specific project requested by customers, based on the Company's know-how. These specific developments, recorded as services, constitute an important lever for the generation of new development and industrialization programs and the Company wishes to continue on this work path.

ABOUT BIOCORP